STAT

APRIL 29, 2024

Scientists who know about the types of pathogens — E. coli and Salmonella among them — that can be transmitted in raw milk generally think drinking unpasteurized milk is a bad idea. But right now, they believe, the danger associated with raw milk may have gone to a whole new level. “If I were in charge, for the moment I would forbid the selling of raw milk,” said Thijs Kuiken, a pathologist in the department of viroscience at Erasmus Medical Center in Rotterdam,

364

364

PharmaVoice

APRIL 29, 2024

The company's schizophrenia drug picked up in its $14 billion acquisition of Karuna Therapeutics recently generated positive long-term data from its phase 3 program.

162

162

STAT

APRIL 29, 2024

“Going to medical Spanish class really isn’t worth my time. I’d rather use the time to do research,” one of my classmates told me during the first week of my first year of medical school. Such a comment was my introduction to the publish-or-perish environment that is increasingly pervasive amongst medical students. Before then, I had known publish-or-perish as something for those seeking tenure at universities.

Medical Schools 363

Medical Schools Communication 363

PharmaVoice

APRIL 29, 2024

Michelle Werner shares how the lessons from her resumé — and personal experience — are driving her work with novel therapeutics.

147

147

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

APRIL 29, 2024

In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs of a study it ran for a tuberculosis treatment regimen and maintained this is the first time that expenses incurred for an individual clinical trial had been publicized. Moreover, the charity argued that its decision should help undercut a long-standing contention by drug companies that high prices for their medicines can be justified by research costs, even though these expenses are never disc

352

352

pharmaphorum

APRIL 29, 2024

Get to know Dr Jay Shah, a prominent figure in the field of cardiovascular medicine, as he answers 12 intriguing questions about his role as Chief Medical Officer at Aktiia and his insights into the field.

124

124

pharmaphorum

APRIL 29, 2024

A partnership between Huma Therapeutics and Merck KGaA to develop digital support tools for cancer patients has borne fruit with the launch of a bladder cancer app in the UK

118

118

STAT

APRIL 29, 2024

WASHINGTON — The Biden administration’s plan to improve cybersecurity at hospitals starts off with incentives, but eventually hospitals will face penalties for not adopting measures to protect patient data, HHS Deputy Secretary Andrea Palm said Monday. In February, a cyberattack against Change Healthcare, a UnitedHealth Group subsidiary that operates the largest medical claims clearinghouse in the country, left many doctors unable to get paid by Medicare.

Hospitals 320

Hospitals 320

pharmaphorum

APRIL 29, 2024

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi (mavorixafor) can be used in patients aged 12 and over with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, a congenital immunodeficiency characterised by low neutrophil counts that affects fewer than 1,000 people in the US.

111

111

STAT

APRIL 29, 2024

The Food and Drug Administration will start actively regulating tests developed in laboratories, with some exemptions, the agency announced on Monday. The agency’s action, which is expected to face legal challenges in courts, comes after Congress failed to pass a law to regulate such tests. The tests have not faced FDA scrutiny historically, as the agency considered them low-risk.

299

299

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

APRIL 29, 2024

Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (GIST) therapy Qinlock. Ono is offering $26.50 per share in cash for the Waltham, Massachusetts-based company, saying the deal will enable it to “build a robust presence in oncology,” one of the group’s key priority areas.

111

111

STAT

APRIL 29, 2024

Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of cancer drugs, for $2.4 billion.  The all-cash deal values Diciphera at $25.60 per share, or a 75% premium to its Friday closing stock price. Deciphera markets a drug called Qinlock for patients with advanced gastrointestinal stromal tumors, or GIST, a type of cancer that begins in the digestive system.

296

296

pharmaphorum

APRIL 29, 2024

CHMP backs EU approval of J&J's Rybrevant as a first-line therapy for NSCLC with EGFR exon 30 insertion mutations, filling a void left after Takeda's Exkivity was pulled from sale

109

109

STAT

APRIL 29, 2024

The pharmaceutical industry saw its reputation slip last year among patient advocacy groups thanks to growing concern about the rising prices for medicines and a lack of confidence prompted by increasing shortages, according to a new survey. Of more than 2,500 groups queried, 57% reported that the industry maintained an “excellent” or “good” reputation as it goes about the business of developing and providing medicines.

290

290

Pharmaceutical Commerce

APRIL 29, 2024

A one-on-one with Thermo Fisher’s Wilfredo Marin, who dives into the value of ultra-low temperature storage, the need for flexibility in the cold chain logistics space, and more.

105

105

STAT

APRIL 29, 2024

I remember the day I left the military after six years of active-duty service. The crisp salute, the finality of it all. I was stepping into a world vastly different from the regimented life I had known. As a third-generation veteran, the military was more than a career; it was a legacy. But what I didn’t realize then was that leaving the military would mean entering a labyrinth of health care bureaucracy that seemed designed to confound and discourage.

289

289

BioPharma Dive

APRIL 29, 2024

Consideration of sustainability early in process development, throughout the entire development cycle, and across the entire supply chain must also become common practice.

Pharmaceutical Manufacturing 106

Pharmaceutical Manufacturing 106

STAT

APRIL 29, 2024

A tentative settlement has been reached in a long-running shareholder lawsuit that accused health care activist investor Alex Denner of making nearly $50 million from insider trading in connection with the 2018 acquisition of Bioverativ. Denner, managing partner of Sarissa Capital Management, a health care hedge fund, had denied the accusations in the lawsuit filed in 2020 with Delaware’s Court of Chancery.

275

275

Pharmafile

APRIL 29, 2024

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe haemophilia B. The post Pfizer’s Beqvez approved by FDA for haemophilia B treatment appeared first on Pharmafile.

105

105

STAT

APRIL 29, 2024

WASHINGTON — Medical device maker Philips said Monday it will pay $1.1 billion to settle hundreds of personal injury lawsuits in the U.S. over its defective sleep apnea machines, which have been subject to a massive global recall. The Dutch manufacturer did not admit any fault and said it reached the agreement to resolve any uncertainty over the cases.

266

266

Pharma Times

APRIL 29, 2024

The new process makes generating active pharmaceutical ingredients quicker and easier

141

141

STAT

APRIL 29, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online meetings, phone calls, and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So to give it a nudge in a better direction, we are firing up the coffee kettle to brew some cups of stimulation.

260

260

pharmaphorum

APRIL 29, 2024

Explore the latest personalised strategies in the field of obesity medicine, including the use of GLP-1 agonists, in today's evolving landscape.

111

111

STAT

APRIL 29, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning! Today, we learn there are some serious safety concerns around an experimental blood cancer drug from MorphoSys that has been the centerpiece of Novartis’ plan to acquire the company for $3 billion. Also, Doctors Without Borders is challenging the pharmaceutical industry to be more transparent about its dollars and cents, and we see more movement

Immunity 244

Immunity Immunization Vaccines 244

BioPharma Dive

APRIL 29, 2024

The drug benefited people whose tumors have “ultralow” levels of HER2 protein, a result that could extend its reach in HER2-positive breast cancer.

105

105

The Luxe Pharmacist

APRIL 29, 2024

Conner & I are living our best DINK (dual income no kids) life and took a long weekend to go to Italy last week. We mainly went to see a rivalry soccer game between AC Milan and Inter Milan, which has been on Conner’s bucket list for years and I’ll never turn down a trip to Italy so we made it happen. I’m recapping our trip with general tips and must sees below!

Grocery Stores 98

Grocery Stores 98

pharmaphorum

APRIL 29, 2024

George Medicines has appointed former Ironwood CEO Mark Mallon to lead the company as it tries to get its triple therapy for hypertension over the finish line.

104

104

Express Pharma

APRIL 29, 2024

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (US FDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), determined by the FDA to be bioequivalent to Advil Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC), of Haleon US Holdings. Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the US by Glenmark Therapeutics, US.

98

98

Welltopia Pharmacy

APRIL 29, 2024

Vitamins For hormones play a vital role in regulating various physiological processes within the body, including metabolism, growth and development, mood,

103

103

Express Pharma

APRIL 29, 2024

In this special edition of the Express Pharma-NutrifyToday Boardroom Series, we introduce you to Anand Swaroop, Ph.D., a biochemist, founder and president of the evidence-based nutritional ingredient supplier Cepham and co-founder of Nutrify Today. He is also one of the six Growth Guardians who will judge the merit of the contestants during the Nutrify C Suite Sumflex – Innovation Battlefield.

97

97

Outsourcing Pharma

APRIL 29, 2024

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

Drug Development 90

Drug Development 90

The Pharmacist

APRIL 29, 2024

The Department of Health and Social Care (DHSC) has published the first list of April price concessions. Community Pharmacy England (CPE) highlighted that the announcement, which was made on Friday, ‘comes late in the month’ and follows imposed changes to the way that price concessions are calculated. From this month, both category M prices and […] The post First April price concessions published appeared first on The Pharmacist.

Community Pharmacies 89

Community Pharmacies 89

Outsourcing Pharma

APRIL 29, 2024

Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).

89

89

Express Pharma

APRIL 29, 2024

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.

Chemotherapy 86

Chemotherapy 86

Pharma Times

APRIL 29, 2024

The method has the potential to be used to deliver RNA to the bloodstream for a range of diseases

111

111